Is Brigatinib/Brigatinib on the market?

Brigatinib/Brigatinib (Brigatinib), originally named AP26113, is a small molecule anti-tumor anaplastic lymphoma kinase (ALK) inhibitor developed by ARIAD Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceuticals. In April 2017, brigatinib received accelerated approval in the United States for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib. The safety of brigatinib is considered controllable, and the European Medicines Agency believes that the benefits of brigatinib outweigh the risks, so it has been marketed in the EU.

In a multinational phase III study (ALTA-1L) of this patient population, brigatinib significantly improved blinded independent review committee-assessed median progression-free survival (PFS), confirmed objective response (OR) rate, and confirmed intracranial OR rate compared with crizotinib. In this study, tolerability was manageable and no new safety issues were identified. Although final analytical data are still awaited, brigatinib therapy expands the first-line treatment options for this patient population, which includes patients with central nervous system metastases.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).